OCULAR THERAPEUTIX, INC Amortization of Debt Discount (Premium)
OCULAR THERAPEUTIX, INC (OCUL) reported Amortization of Debt Discount (Premium) of $412.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC amortization of debt discount (premium) for fiscal 2024 was $412.00K, a 79.82% decline from fiscal 2023.
- OCULAR THERAPEUTIX, INC amortization of debt discount (premium) for fiscal 2023 was $2.04M.
| Period end | Amortization of Debt Discount (Premium) 12 month |
|---|---|
| 2024-12-31 | $412.00K 10-K · filed 2026-02-05 |
| 2023-12-31 | $2.04M 10-K · filed 2026-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |